By Notice dated March 11, 2003, and published in the Federal Register on April 2, 2003, (68 FR 16091), Novartis Pharmaceuticals Corporation, Attn: Security Department, Building 103, Room 335, 59 Route 10, East Hanover, New Jersey 07936, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic class of controlled substance listed below:
The firm plans to produce bulk product and finished dosage units for distribution to its customers.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Novartis Pharmaceuticals Corporation to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Novartis Pharmaceuticals Corporation to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.Start Signature
Dated: July 30, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 03-21044 Filed 8-15-03; 8:45 am]
BILLING CODE 4410-09-M